Challenging the monopoly of Europe and America, Chinese and Indian manufacturers have laid out the track of diet pills. For some time, GLP-1 (glucagon-like peptide -1) diet pills have caught fire in the United States and other western countries, and gradually marched into emerging markets. At present, two major pharmaceutical companies, Novo Nordisk in Denmark and Lilly in the United States, occupy most of the market share in the field of GLP-1 diet pills, but other pharmaceutical companies are also actively deploying the track. In 2026, Novo Nordisk's patent on smeagoutide will expire in China and India, while the patent on liraglutide, the main effective ingredient of the previous generation of GLP-1 diet pills, has expired in China and India. The industry believes that China and India, as two emerging markets, have a strong momentum of innovation and development in the pharmaceutical industry of both countries, and have great potential in the GLP-1 diet pills track. The entry of Chinese and Indian pharmaceutical companies will make the international competition in the field of GLP-1 diet pills more intense. (Global Times)Fat Donglai: Measures will be taken to control purchasing behavior. Fat Donglai released the control measures on purchasing behavior, saying that from December 14, Fat Donglai will implement the following series of measures to control, including improving the real-name information of membership cards, implementing dynamic code checkout for membership cards, restricting the purchase of goods, limiting the flow of stores, and quickly processing purchasing mechanisms.Famous products Ye Guofu: Promote high-quality development with high-quality consumption. Recently, Ye Guofu, the founder, chairman and CEO of Famous Products, talked with the media about the 2024 Central Economic Work Conference and expressed confidence in the consumer market in China next year. Ye Guofu said that benefiting people's livelihood is widely expected and actively responds to the spirit of the Central Economic Work Conference. Enterprises have the responsibility to fully support and cooperate with the state to do a good job in consumption, boost consumption, enhance consumption capacity, and promote high-quality development with high-quality consumption.
CICC: Give GM an initial rating that outperforms the broader market, with a target price of $65.In the first two weeks of December, Wuhan sold a total of 22 residential plots, with a total investment of more than 11 billion yuan. In the first two weeks of December, Wuhan has carried out three batches of residential plots, with a total investment of more than 11 billion yuan. On December 13th, Wuhan successfully sold six residential plots, including one in Hanyang District, East Lake High-tech Zone, Hongshan District and huangpi district, and two in Qingshan District. The total land area of 6 plots is 214,964 square meters, the total planned construction area is 726,285.4 square meters, and the total starting price is 5.457 billion yuan. In the end, all six plots were sold at the reserve price, with a total income of 5.457 billion yuan, including Yangchun Lake in Hongshan District, OCT, and Hanyang District, Wuhan Huijing Real Estate, a private enterprise.Al Barawi, Chairman of the Bid Committee for the World Cup in Saudi Arabia: Welcome China investors to participate in the preparations for the World Cup. The special meeting of the International Football Federation recently announced that Saudi Arabia will host the 2034 World Cup. In an exclusive interview with reporters, Hamad Al Barawi, chairman of Saudi Arabia's bid committee for the 2034 World Cup, said that Saudi Arabia is taking the opportunity of hosting the World Cup to step onto the global stage, constantly showing its firm support for the development of sports industry and its enthusiasm and confidence in football, and welcomes China investors to participate in the preparations for the World Cup. (Xinhua News Agency)
The latest research results support Harvard's discovery that Novo Nordisk's diet drug Ozempic is related to rare visual loss. The latest research shows that Novo Nordisk's best-selling diet drug Ozempic may increase the risk of a rare visual loss disease-nonarteritic anterior ischemic optic neuropathy (NAION). This finding supports similar findings published earlier by the Harvard team. A research team composed of the University of Southern Denmark, the Norwegian Institute of Public Health and the University of Copenhagen found that diabetic patients who used Ozempic were twice as likely to be diagnosed with NAION as other drugs. NAION occurs when the blood flow decreases and damages the optic nerve. The risk of eye conditions is still low; Patients should pay attention. Novo Nordisk Denmark's share price once fell more than 3.3%.According to the information released by the National Earthquake Center of the University of Chile, a 6.3-magnitude earthquake occurred in the Maule region of central Chile on the 13th. (Xinhua News Agency)The position ETF--iShares Gold Trust, the world's largest gold ETF, decreased by 4.6 tons compared with the previous trading day, and the current position is 863.9 tons.